The path to approved Alzheimer's treatments starts with a better way to diagnose patients. Bill Gates and ADDF Co-Founder Leonard A. Lauder partnered to adopt a new approach that brings together philanthropic capital with a venture mindset to advance bold ideas for easier, more accurate, and earlier diagnosis of Alzheimer's disease and related dementias.

Currently available tests for Alzheimer's are expensive and invasive. The development of reliable and affordable biomarker tests for Alzheimer’s— just as cholesterol is an early biomarker for heart disease risk— has the potential to revolutionize how we approach the disease. Biomarkers will allow us to better understand how the disease progresses, improve clinical trial design, and more accurately monitor response to treatments. All are critical to the development of effective drugs for the prevention and treatment of Alzheimer’s.

Launched in July 2018, the Diagnostics Accelerator has mobilized commitments totaling $50 million from Bill Gates, Leonard A. Lauder, the Dolby family, the Charles and Helen Schwab Foundation, and additional partners including Jeff Bezos and MacKenzie Scott, The Association for Frontotemporal Degeneration, and others, to bring focus, resources, and urgency required to solve this important problem.

The Diagnostics Accelerator is accepting applications on a rolling basis.


Funding Type
Sponsor: Rolling